Counselors in Dublin, NH Accepting Medicare
5 Counselors found. Showing 1 - 5
 Ross A Garofalo, BA Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 3 Pierce Rd, Dublin, NH 03444 Phone: 603-563-8107 |
Ross Whitney Davidson, LCMHC, MLADC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 489 Main St, Dublin, NH 03444 Phone: 603-831-8000 Fax: 603-912-7607 |
 Emily Wilkins, LCMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 3 Pierce Rd, Dublin, NH 03444 Phone: 603-563-8107 Fax: 603-563-7083 |
Jane T Quigley, MLADC, LCMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 3 Pierce Rd, Dublin, NH 03444 Phone: 603-563-8501 |
Rosemary Moran Weidner, L.A.D.C. Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 65 Gerry Rd., Dublin, NH 03444 Phone: 603-563-8620 |
News Archive
Experts outline five principles to reduce incidence of diagnostic errors
Errors in diagnosis place a heavy financial burden on an already costly health care system and can be devastating for affected patients. Strengthening certain aspects of a new and evolving model of comprehensive and coordinated primary care could potentially address this highly relevant, but underemphasized safety concern, say Mark Graber, M.D., of Stony Brook University Medical Center, and Hardeep Singh, M.D., M.P.H., of Baylor College of Medicine, in a commentary published in the July 28 issue of the Journal of the American Medical Association.
AdvanSource Biomaterials' polymer product lines comply with the guidelines of European Council Decision
AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced that its polymer product lines are compliant with measures applying to the processing of certain animal waste to protect against transmissible spongiform encephalopathies as set forth in European Council Decision 1999/534/EC.
Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
U.S., South African scientists launch $60 million HIV/TB research initiative
Scientists from the U.S. Howard Hughes Medical Institute and South Africa's University of KwaZulu Natal on Wednesday announced the launch of a $60 million, 10-year initiative to establish a new research facility to examine the associations between HIV and tuberculosis, the Boston Globe reports.
› Verified 7 days ago